Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Doruk Erkan

Showing results (51-60 of 193) with videos related to

Pageof 20
Sort By:
The Journal of Rheumatology|August 16, 2002
Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: is it time to update the guidelines?Yusuf Yazici, Doruk Erkan, Stephen A Paget
Best Practice & Research. Clinical Haematology|December 9, 2022
COVID-19 and antiphospholipid antibodiesAyesha Butt, Doruk Erkan, Alfred Ian Lee
Arthritis and Rheumatism|September 11, 2012
Cognitive or cosmetic dysfunction?Omer Uludag, Doruk Erkan, Michael D Lockshin
Current Opinion in Rheumatology|November 25, 2015
Recognition and management of antiphospholipid syndromeMaria Gerosa, Pier Luigi Meroni, Doruk Erkan
Arthritis and Rheumatism|December 16, 2003
Catastrophic antiphospholipid syndrome: where do we stand?Doruk Erkan, Ricard Cervera, Ronald A Asherson
Pathophysiology : the Official Journal of the International Society for Pathophysiology|May 18, 2010
Cognitive dysfunction and white matter abnormalities in antiphospholipid syndromeDoruk Erkan, Elizabeth Kozora, Michael D Lockshin
Arthritis Care & Research|December 31, 2013
Reply: To PMID 23861221Cecilia B Chighizola, Laura Andreoli, Doruk Erkan
Current Opinion in Immunology|April 21, 2026
Understanding antiphospholipid syndrome clinical phenotypes with the guidance of antiphospholipid antibody-related pathogenic mechanismsEcem Sevim, Zeynep B Erton, Doruk Erkan
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|February 27, 2024
Persistent Moderate-to-High Levels of Isolated Anticardiolipin Antibody IgA or Anti-β<sub>2</sub>-Glycoprotein-I IgA Isotypes: Do They Have Any Clinical Relevance?Ayse Bahar Keleşoğlu Dinçer, Jonathan Thaler, Doruk Erkan
Nature Reviews. Drug Discovery|December 2, 2004
Challenges in bringing the bench to bedside in drug development for SLEJoan T Merrill, Doruk Erkan, Jill P Buyon
Pageof 20

Showing results (51-60 of 193) with videos related to

Sort By:
Pageof 20
The Journal of Rheumatology|August 16, 2002
Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: is it time to update the guidelines?Yusuf Yazici, Doruk Erkan, Stephen A Paget
Best Practice & Research. Clinical Haematology|December 9, 2022
COVID-19 and antiphospholipid antibodiesAyesha Butt, Doruk Erkan, Alfred Ian Lee
Arthritis and Rheumatism|September 11, 2012
Cognitive or cosmetic dysfunction?Omer Uludag, Doruk Erkan, Michael D Lockshin
Current Opinion in Rheumatology|November 25, 2015
Recognition and management of antiphospholipid syndromeMaria Gerosa, Pier Luigi Meroni, Doruk Erkan
Arthritis and Rheumatism|December 16, 2003
Catastrophic antiphospholipid syndrome: where do we stand?Doruk Erkan, Ricard Cervera, Ronald A Asherson
Pathophysiology : the Official Journal of the International Society for Pathophysiology|May 18, 2010
Cognitive dysfunction and white matter abnormalities in antiphospholipid syndromeDoruk Erkan, Elizabeth Kozora, Michael D Lockshin
Arthritis Care & Research|December 31, 2013
Reply: To PMID 23861221Cecilia B Chighizola, Laura Andreoli, Doruk Erkan
Current Opinion in Immunology|April 21, 2026
Understanding antiphospholipid syndrome clinical phenotypes with the guidance of antiphospholipid antibody-related pathogenic mechanismsEcem Sevim, Zeynep B Erton, Doruk Erkan
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|February 27, 2024
Persistent Moderate-to-High Levels of Isolated Anticardiolipin Antibody IgA or Anti-β<sub>2</sub>-Glycoprotein-I IgA Isotypes: Do They Have Any Clinical Relevance?Ayse Bahar Keleşoğlu Dinçer, Jonathan Thaler, Doruk Erkan
Nature Reviews. Drug Discovery|December 2, 2004
Challenges in bringing the bench to bedside in drug development for SLEJoan T Merrill, Doruk Erkan, Jill P Buyon
Pageof 20